Status:
COMPLETED
Special Investigation (Follow-up Survey of the Study of Adalimumab (D2E7) for Prevention of Joint Destruction in Patients With Rheumatoid Arthritis in Japan (M06-859 (NCT00870467))
Lead Sponsor:
AbbVie (prior sponsor, Abbott)
Conditions:
Rheumatoid Arthritis
Eligibility:
All Genders
20+ years
Brief Summary
The present survey was conducted to evaluate the effectiveness and safety of treatment with adalimumab during the 52-week period following completion of the treatment period in Study NCT00870467 (M06-...
Detailed Description
This survey was conducted to assess the risk and benefit of continuing or discontinuing biological therapy with adalimumab (Humira) during the 52-week period following completion of the treatment peri...
Eligibility Criteria
Inclusion
- The participants were patients who continued treatment with adalimumab until the end of the treatment period in the NCT00870467(M06-859) study and provided informed consent to participate in the present follow-up survey.
Exclusion
- Participants who used biological agents other than adalimumab after the period of treatment in the NCT00870467(M06-859) study were excluded from the present follow-up study.
Key Trial Info
Start Date :
March 1 2010
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
October 1 2012
Estimated Enrollment :
220 Patients enrolled
Trial Details
Trial ID
NCT01163292
Start Date
March 1 2010
End Date
October 1 2012
Last Update
July 6 2018
Active Locations (75)
Enter a location and click search to find clinical trials sorted by distance.
1
Site Reference ID/Investigator# 54680
Anjo, Japan
2
Site Reference ID/Investigator# 54677
Aomori, Japan
3
Site Reference ID/Investigator# 54516
Chiba, Japan
4
Site Reference ID/Investigator# 54660
Chiba, Japan